Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and
represents the major therapeutic target for treating metastatic prostate cancer (mPC) …

Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the
gold standard options for treating prostate cancer (PCa). These are initially effective, as …

The transition from castration-resistant prostate adenocarcinoma (CRPC) to neuroendocrine
prostate cancer (NEPC) has emerged as an important mechanism of treatment resistance …

Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …

Altered lipid metabolism is increasingly recognized as a signature of cancer cells. Enabled
by label-free Raman spectromicroscopy, we performed quantitative analysis of lipogenesis …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …